WO2019092179A1 - Compositions pharmaceutiques comprenant zs-9 - Google Patents

Compositions pharmaceutiques comprenant zs-9 Download PDF

Info

Publication number
WO2019092179A1
WO2019092179A1 PCT/EP2018/080759 EP2018080759W WO2019092179A1 WO 2019092179 A1 WO2019092179 A1 WO 2019092179A1 EP 2018080759 W EP2018080759 W EP 2018080759W WO 2019092179 A1 WO2019092179 A1 WO 2019092179A1
Authority
WO
WIPO (PCT)
Prior art keywords
μιη
pharmaceutical composition
composition according
absorption inhibitor
poloxamer
Prior art date
Application number
PCT/EP2018/080759
Other languages
English (en)
Inventor
Anke Schuster
Herbert Silberberger
Johannes Raneburger
Miha Jaklic
Gaj STAVBER
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of WO2019092179A1 publication Critical patent/WO2019092179A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B39/00—Compounds having molecular sieve and base-exchange properties, e.g. crystalline zeolites; Their preparation; After-treatment, e.g. ion-exchange or dealumination
    • C01B39/02—Crystalline aluminosilicate zeolites; Isomorphous compounds thereof; Direct preparation thereof; Preparation thereof starting from a reaction mixture containing a crystalline zeolite of another type, or from preformed reactants; After-treatment thereof
    • C01B39/026—After-treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Geology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Materials Engineering (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

ZS-9 est un nouveau tamis moléculaire efficace utilisé dans des compositions pour le traitement de l'hyperkaliémie, d'une néphropathie chronique, d'une maladie vasculaire coronaire, du diabète sucré et d'un rejet de greffe. Étant donné que des quantités plutôt importantes du produit doivent être ingérées, une bonne capacité d'acceptation est d'une grande importance pour garantir l'observance du patient. Il a été découvert qu'une fine grosseur de particule permet différentes formulations de goût et de sensation en bouche améliorés pour le patient. La formulation peut en outre comprendre un inhibiteur d'absorption qui capture les particules fines dans une matrice gonflante, ce qui, d'une part, empêche l'absorption dans le tractus gastro-intestinal et, d'autre part, protège les tamis moléculaires de l'environnement acide fort dans l'estomac. Facultativement, un excipient mucoadhésif peut être ajouté pour allonger le temps de passage dans le tractus intestinal et augmenter ainsi encore davantage la quantité de potassium lié.
PCT/EP2018/080759 2017-11-10 2018-11-09 Compositions pharmaceutiques comprenant zs-9 WO2019092179A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17201189 2017-11-10
EP17201182.7 2017-11-10
EP17201182 2017-11-10
EP17201189.2 2017-11-10

Publications (1)

Publication Number Publication Date
WO2019092179A1 true WO2019092179A1 (fr) 2019-05-16

Family

ID=64277689

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2018/080759 WO2019092179A1 (fr) 2017-11-10 2018-11-09 Compositions pharmaceutiques comprenant zs-9

Country Status (1)

Country Link
WO (1) WO2019092179A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012109590A2 (fr) 2011-02-11 2012-08-16 Zs Pharma, Inc Silicate de zirconium microporeux pour traitement de l'hyperkaliémie
WO2013188431A1 (fr) * 2012-06-11 2013-12-19 ZS Pharma, Inc. Production de silicate de zirconium microporeux amélioré
WO2015070019A1 (fr) * 2013-11-08 2015-05-14 ZS Pharma, Inc. Silicate de zirconium microporeux pour le traitement de l'hyperkaliémie
WO2017066128A1 (fr) * 2015-10-14 2017-04-20 ZS Pharma, Inc. Compositions de silicate de zirconium à usage prolongé et procédés d'utilisation correspondants

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012109590A2 (fr) 2011-02-11 2012-08-16 Zs Pharma, Inc Silicate de zirconium microporeux pour traitement de l'hyperkaliémie
WO2013188431A1 (fr) * 2012-06-11 2013-12-19 ZS Pharma, Inc. Production de silicate de zirconium microporeux amélioré
WO2015070019A1 (fr) * 2013-11-08 2015-05-14 ZS Pharma, Inc. Silicate de zirconium microporeux pour le traitement de l'hyperkaliémie
WO2017066128A1 (fr) * 2015-10-14 2017-04-20 ZS Pharma, Inc. Compositions de silicate de zirconium à usage prolongé et procédés d'utilisation correspondants

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AM. J. KIDNEY DIS., vol. 63, no. 5, 2014, pages A115
DAVID K. PACKHAM ET AL: "Pharmacodynamics and pharmacokinetics of sodium zirconium cyclosilicate [ZS-9] in the treatment of hyperkalemia", EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, vol. 12, no. 5, 3 May 2016 (2016-05-03), GB, pages 567 - 573, XP055413211, ISSN: 1742-5255, DOI: 10.1517/17425255.2016.1164691 *
LINDER ET AL., PHARMACOTHERAPY, vol. 36, no. 8, 2016, pages 923
PHARMACOTHERAPY, vol. 36, no. 8, 2016, pages 923
SCHAFER-KORTING M.: "Drug Delivery", 2010, SPRINGER-VERLAG

Similar Documents

Publication Publication Date Title
JP4573397B2 (ja) 速崩壊性固形製剤
JP5421775B2 (ja) オキシコドンを含む顆粒及び口腔内崩壊錠剤
DE60123381T2 (de) Neue dosisformen von substituierten benzimidazolen und verfahren zur deren verwendung
US9974805B2 (en) Phosphate binder formulation for simple dosing
KR101565621B1 (ko) 저치환도 히드록시프로필셀룰로오스 수분산액을 이용한 습식 조립 타정법
JPH0248525B2 (fr)
JP2635407B2 (ja) 医薬咀しゃく錠組成物
KR20100096179A (ko) 구강 붕해정
KR20100126266A (ko) 약학 조성물
KR20110119714A (ko) 포스페이트 결합 폴리머를 포함하는 약학적 조성물
KR20030097892A (ko) 의약 배합제
WO2011110939A2 (fr) Compositions pharmaceutiques de benzhydrylpipérazines substituées
MX2012000048A (es) Formulaciones de comprimidos de 3-cianoquinolina y usos de los mismos.
JP2711759B2 (ja) 止瀉剤組成物
EP1474154B1 (fr) Ameliorations apportees a des compositions ou liees a ces compositions
EP3212179A1 (fr) Particules de cadotril
JP4961338B2 (ja) ナイアシンの経口投与用徐放性組成物
KR101595107B1 (ko) 플라보이드 분획 및 잔탄 검을 포함하는 경구 현탁액 형태의 약학 조성물
WO2019092179A1 (fr) Compositions pharmaceutiques comprenant zs-9
EP3735238A1 (fr) Composition pharmaceutique orale stable de citrate ferrique
WO2004089343A1 (fr) Comprimes hydrosolubles
EP3157516A1 (fr) Compositions pharmaceutiques comprenant du citrate ferrique et procédés de fabrication de celles-ci
CN103919790A (zh) 一种磺胺脒-甲氧苄啶泡腾片的制备方法
KR20150096787A (ko) Ｎ-[5-[2-(3,5-디메톡시페닐)에틸]-2ｈ-피라졸-3-일]-4-[(3ｒ,5ｓ)-3,5-디메틸피페라진-1-일]벤즈아미드의 약학 제제
WO2020209350A1 (fr) Comprimé oral à désintégration rapide pour le traitement du diabète

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18800921

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18800921

Country of ref document: EP

Kind code of ref document: A1